Gold prices dropped to a new low of $4,104 before bouncing back, supported by the 78.6% Fibonacci retracement level. This technical support suggests a potential short-term rally, although the overall trend remains bearish with resistance at $4,226. A close above this resistance could signal a reversal, but caution is advised as further declines may follow after any recovery. Investors should watch the $4,104 support and $4,226 resistance levels closely for clues on gold's next move.
Gold prices recently touched a low of $4,104 before rebounding, a key support level noted in the forecast. For readers following US stock market activity on Pluang as of Oct 07, 2026 03:02 WIB: out of 150 priced US stocks, 86 rose and 61 fell. Notable movers include Norwegian Cruise Line Holdings Ltd (NCLH) at USD 15.60 with a 1-day change of +4.91% and Pluang order activity showing 26% Sell / 74% Buy, Cisco Systems Inc (CSCO) at USD 117.93 up +4.53%, and Carnival Corp (CCL) at USD 26.59 with 0% Sell / 100% Buy activity.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
U.S. spot Solana ETFs experienced $3.7 million in net outflows on October 6, marking the second consecutive day of withdrawals. The Grayscale Solana Trust was the main contributor to this decline, while six other funds showed no net flow. Although th...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
